{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:46:31Z","timestamp":1791960391128,"version":"4.3.4"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222567\/Z\/21\/Z"],"award-info":[{"award-number":["222567\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000697","name":"Rhodes Scholarships","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000697","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["BBC\/F\/21\/220106"],"award-info":[{"award-number":["BBC\/F\/21\/220106"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-026-00884-6","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:02:40Z","timestamp":1790586160000},"page":"941-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic upregulation of gene expression in inherited cardiomyopathies from current approaches to future directions"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-7000","authenticated-orcid":false,"given":"Rosemary B.","family":"Kirk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-3667","authenticated-orcid":false,"given":"Celine F.","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-9016","authenticated-orcid":false,"given":"Hugh","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4671-2030","authenticated-orcid":false,"given":"Christopher N.","family":"Toepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"884_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41569-020-0428-2","volume":"18","author":"WJ McKenna","year":"2021","unstructured":"McKenna, W. J. & Judge, D. P. Epidemiology of the inherited cardiomyopathies. Nat. Rev. Cardiol. 18, 22\u201336 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"884_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1136\/bmj.l1570","volume":"365","author":"C Miles","year":"2019","unstructured":"Miles, C., Fanton, Z., Tome, M. & Behr, E. R. Inherited cardiomyopathies. BMJ 365, 1570 (2019).","journal-title":"BMJ"},{"key":"884_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra0902923","volume":"364","author":"H Watkins","year":"2011","unstructured":"Watkins, H., Ashrafian, H. & Redwood, C. Inherited cardiomyopathies. N. Engl. J. Med. 364, 1643\u20131656 (2011).","journal-title":"N. Engl. J. Med."},{"key":"884_CR4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/eurheartj\/ehaa141","volume":"41","author":"CA James","year":"2020","unstructured":"James, C. A., Syrris, P., Van Tintelen, J. P. & Calkins, H. The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. Eur. Heart J. 41, 1393\u20131400 (2020).","journal-title":"Eur. Heart J."},{"key":"884_CR5","doi-asserted-by":"publisher","first-page":"100854","DOI":"10.1016\/j.jbc.2021.100854","volume":"297","author":"C Suay-Corredera","year":"2021","unstructured":"Suay-Corredera, C. et al. Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy. J. Biol. Chem. 297, 100854 (2021).","journal-title":"J. Biol. Chem."},{"key":"884_CR6","doi-asserted-by":"publisher","first-page":"1296389","DOI":"10.3389\/fcvm.2023.1296389","volume":"10","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Comprehensive review on gene mutations contributing to dilated cardiomyopathy. Front. Cardiovasc. Med. 10, 1296389 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"884_CR7","doi-asserted-by":"crossref","unstructured":"Ercanbrack, W. S. et al. Frataxin deficiency and the pathology of Friedreich\u2019s ataxia across tissues. Tissue Barriers 13, 2462357 (2025).","DOI":"10.1080\/21688370.2025.2462357"},{"key":"884_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41434-025-00561-6","volume":"32","author":"K Chwalenia","year":"2025","unstructured":"Chwalenia, K. et al. AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects. Gene Ther. 32, 447\u2013461 (2025).","journal-title":"Gene Ther."},{"key":"884_CR9","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2023.08.014","volume":"82","author":"KN Hong","year":"2023","unstructured":"Hong, K. N. et al. International consensus on differential diagnosis and management of patients with Danon disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 82, 1628\u20131647 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"884_CR10","doi-asserted-by":"publisher","first-page":"e027373","DOI":"10.1161\/JAHA.122.027373","volume":"11","author":"HQ Qu","year":"2022","unstructured":"Qu, H. Q., Feldman, A. M. & Hakonarson, H. Genetics of BAG3: a paradigm for developing precision therapies for dilated cardiomyopathies. J. Am. Heart Assoc. 11, e027373 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"884_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.cardfail.2023.08.016","volume":"29","author":"KF Rosario","year":"2023","unstructured":"Rosario, K. F. et al. LMNA cardiomyopathy: important considerations for the heart failure clinician. J. Card. Fail. 29, 1657\u20131666 (2023).","journal-title":"J. Card. Fail."},{"key":"884_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd7287","volume":"13","author":"Q McAfee","year":"2021","unstructured":"McAfee, Q. et al. Truncated titin proteins in dilated cardiomyopathy. Sci. Transl. Med. 13, eabd7287 (2021).","journal-title":"Sci. Transl. Med."},{"key":"884_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3079","volume":"13","author":"A Fomin","year":"2021","unstructured":"Fomin, A. et al. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations. Sci. Transl. Med. 13, eabd3079 (2021).","journal-title":"Sci. Transl. Med."},{"key":"884_CR14","doi-asserted-by":"crossref","unstructured":"Ghahremani, S. et al. CRISPR activation reverses haploinsufficiency and functional deficits caused by TTN truncation variants. Circulation 149, 1285\u20131297 (2024). Demonstrated that CRISPRa-mediated upregulation of TTN can restore titin expression in hiPSC-derived cardiomyocytes and rescue functional deficits, providing proof of concept for therapeutic upregulation of a haploinsufficient cardiomyopathy gene.","DOI":"10.1161\/CIRCULATIONAHA.123.063972"},{"key":"884_CR15","first-page":"735","volume":"11","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski, J. W., Guo, R., Elliott, P. M. & Ho, C. Y. Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: heart failure state-of-the-art review. Heart Fail. 11, 735\u2013748 (2023).","journal-title":"Heart Fail."},{"key":"884_CR16","doi-asserted-by":"crossref","unstructured":"Desai, M. Y. et al. First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1. Cardiovasc. Res. 121, 2628\u20132631 (2025). Reports initial first-in-human findings for AAV9-mediated MYBPC3 gene replacement in HCM, with good tolerability and limited evidence of increased protein.","DOI":"10.1093\/cvr\/cvaf200"},{"key":"884_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","volume":"1","author":"BJ Maron","year":"2016","unstructured":"Maron, B. J., Rowin, E. J., Casey, S. A. & Maron, M. S. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol. 1, 98\u2013105 (2016).","journal-title":"JAMA Cardiol."},{"key":"884_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ejhf.16","volume":"16","author":"M Merlo","year":"2014","unstructured":"Merlo, M. et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur. J. Heart Fail. 16, 317\u2013324 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"884_CR19","doi-asserted-by":"publisher","first-page":"bio057646","DOI":"10.1242\/bio.057646","volume":"10","author":"M Schmid","year":"2021","unstructured":"Schmid, M. & Toepfer, C. N. Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics. Biol. Open 10, bio057646 (2021).","journal-title":"Biol. Open"},{"key":"884_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green, E. M. et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351, 617\u2013621 (2016).","journal-title":"Science"},{"key":"884_CR21","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson, R. L. et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc. Natl Acad. Sci. USA 115, E8143\u2013E8152 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"884_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat1199","volume":"11","author":"CN Toepfer","year":"2019","unstructured":"Toepfer, C. N. et al. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci. Transl. Med. 11, eaat1199 (2019).","journal-title":"Sci. Transl. Med."},{"key":"884_CR23","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","volume":"141","author":"CN Toepfer","year":"2020","unstructured":"Toepfer, C. N. et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141, 828\u2013842 (2020).","journal-title":"Circulation"},{"key":"884_CR24","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2025","unstructured":"Greenberg, B. et al. Phase 1 study of AAV9. LAMP2B gene therapy in Danon disease. N. Engl. J. Med. 392, 972\u2013983 (2025). Reports the first-in-human evaluation of AAV9-mediated LAMP2B gene replacement in Danon disease, demonstrating cardiac LAMP2 expression and improvement or stabilization of key clinical measures.","journal-title":"N. Engl. J. Med."},{"key":"884_CR25","unstructured":"Rocket Pharmaceuticals. Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease https:\/\/ir.rocketpharma.com\/news-releases\/news-release-details\/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp\/ (2025)."},{"key":"884_CR26","unstructured":"Rocket Pharmaceuticals. Rocket Pharmaceuticals Announces FDA has Lifted the Clinical Hold on the Pivotal Phase 2 trial of RP-A501 for the Treatment of Danon Disease https:\/\/ir.rocketpharma.com\/news-releases\/news-release-details\/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold (2025)."},{"key":"884_CR27","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","volume":"2","author":"WH Bradford","year":"2023","unstructured":"Bradford, W. H. et al. Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics. Nat. Cardiovasc. Res. 2, 1246\u20131261 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"884_CR28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004305","volume":"17","author":"CJ van Opbergen","year":"2024","unstructured":"van Opbergen, C. J. et al. AAV-mediated delivery of plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans. Circ. Genom. Precis. Med. 17, e004305 (2024).","journal-title":"Circ. Genom. Precis. Med."},{"key":"884_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s43856-024-00450-w","volume":"4","author":"I Wu","year":"2024","unstructured":"Wu, I. et al. AAV9:PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy. Commun. Med. 4, 38 (2024).","journal-title":"Commun. Med."},{"key":"884_CR30","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","volume":"2","author":"E Kyriakopoulou","year":"2023","unstructured":"Kyriakopoulou, E. et al. Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat. Cardiovasc. Res. 2, 1262\u20131276 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"884_CR31","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.omtm.2024.101193","volume":"32","author":"JC Chang","year":"2024","unstructured":"Chang, J. C. et al. AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich\u2019s ataxia. Mol. Ther. Methods Clin. Dev. 32, 101193 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"884_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell, J. R. et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat. Med. 31, 332\u2013341 (2025).","journal-title":"Nat. Med."},{"key":"884_CR33","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","volume":"7","author":"J-Y Dong","year":"1996","unstructured":"Dong, J.-Y., Fan, P.-D. & Frizzell, R. A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101\u20132112 (1996).","journal-title":"Hum. Gene Ther."},{"key":"884_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80\u201386 (2010).","journal-title":"Mol. Ther."},{"key":"884_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57481-7","volume":"16","author":"A Greer-Short","year":"2025","unstructured":"Greer-Short, A. et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat. Commun. 16, 2196 (2025).","journal-title":"Nat. Commun."},{"key":"884_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41434-025-00531-y","volume":"32","author":"DC G\u00f3recki","year":"2025","unstructured":"G\u00f3recki, D. C., Kalinski, P. & Pomeroy, J. Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy? Gene Ther. 32, 561\u2013568 (2025).","journal-title":"Gene Ther."},{"key":"884_CR37","doi-asserted-by":"publisher","first-page":"1635586","DOI":"10.3389\/fmed.2025.1635586","volume":"12","author":"M Desai","year":"2025","unstructured":"Desai, M. et al. High rate of seroeligibility among MYBPC3-associated hypertrophic cardiomyopathy patients for TN-201, an adeno-associated virus serotype 9 MYBPC3 gene therapy. Front. Med. 12, 1635586 (2025).","journal-title":"Front. Med."},{"key":"884_CR38","doi-asserted-by":"crossref","unstructured":"Lek, A., Atas, E., Hesterlee, S. E., Byrne, B. J. & B\u00f6nnemann, C. G. Meeting Report: 2022 Muscular Dystrophy Association Summit on \u2018Safety and Challenges in Gene Transfer Therapy\u2019. J. Neuromuscul. Dis. 10, 327\u2013336 (2023).","DOI":"10.3233\/JND-221639"},{"key":"884_CR39","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HC Ertl","year":"2022","unstructured":"Ertl, H. C. Immunogenicity and toxicity of AAV gene therapy. Front. Immunol. 13, 975803 (2022).","journal-title":"Front. Immunol."},{"key":"884_CR40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","volume":"22","author":"TK Kishimoto","year":"2022","unstructured":"Kishimoto, T. K. & Samulski, R. J. Addressing high dose AAV toxicity\u2014\u2018one and done\u2019 or \u2018slower and lower\u2019? Expert Opin. Biol. Ther. 22, 1067\u20131071 (2022).","journal-title":"Expert Opin. Biol. Ther."},{"key":"884_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","volume":"19","author":"B Belbellaa","year":"2020","unstructured":"Belbellaa, B., Reutenauer, L., Messaddeq, N., Monassier, L. & Puccio, H. High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol. Ther. Methods Clin. Dev. 19, 120\u2013138 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"884_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","volume":"24","author":"C Huichalaf","year":"2022","unstructured":"Huichalaf, C. et al. In vivo overexpression of frataxin causes toxicity mediated by iron\u2013sulfur cluster deficiency. Mol. Ther. Methods Clin. Dev. 24, 367\u2013378 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"884_CR43","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 78, 834\u2013841 (2021).","journal-title":"JAMA Neurol."},{"key":"884_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell, J. R. et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial. Muscle Nerve 69, 93\u201398 (2024).","journal-title":"Muscle Nerve"},{"key":"884_CR45","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","volume":"86","author":"A Singh","year":"2024","unstructured":"Singh, A. et al. Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease. Ann. Med. Surg. 86, 4555\u20134559 (2024).","journal-title":"Ann. Med. Surg."},{"key":"884_CR46","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","volume":"33","author":"AJ Hooper","year":"2024","unstructured":"Hooper, A. J., Tang, X. L. & Burnett, J. R. VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert Opin. Investig. Drugs 33, 753\u2013756 (2024).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"884_CR47","doi-asserted-by":"crossref","unstructured":"Chai, A. C. et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat. Med. 29, 401\u2013411 (2023).","DOI":"10.1038\/s41591-022-02176-5"},{"key":"884_CR48","doi-asserted-by":"crossref","unstructured":"Reichart, D. et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat. Med. 29, 412\u2013421 (2023). Demonstrated that in vivo base editing can correct an HCM-causing myosin variant and prevent the development of cardiac hypertrophy and fibrosis in mice.","DOI":"10.1038\/s41591-022-02190-7"},{"key":"884_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade1633","volume":"14","author":"T Nishiyama","year":"2022","unstructured":"Nishiyama, T. et al. Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Sci. Transl. Med. 14, eade1633 (2022).","journal-title":"Sci. Transl. Med."},{"key":"884_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39352-1","volume":"14","author":"M Grosch","year":"2023","unstructured":"Grosch, M. et al. Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy. Nat. Commun. 14, 3714 (2023).","journal-title":"Nat. Commun."},{"key":"884_CR51","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41422-024-00930-7","volume":"34","author":"S Wu","year":"2024","unstructured":"Wu, S. et al. Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice. Cell Res. 34, 327\u2013330 (2024).","journal-title":"Cell Res."},{"key":"884_CR52","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Correction of MYBPC3 c.772G>A splice-site mutation by base editing ameliorates hypertrophic cardiomyopathy in humanized mice. Circ. Res. 138, e327443 (2026).","DOI":"10.1161\/CIRCRESAHA.125.327443"},{"key":"884_CR53","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1161\/CIRCULATIONAHA.110.956839","volume":"123","author":"DE Handy","year":"2011","unstructured":"Handy, D. E., Castro, R. & Loscalzo, J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation 123, 2145\u20132156 (2011).","journal-title":"Circulation"},{"key":"884_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cell.2016.08.056","volume":"167","author":"XS Liu","year":"2016","unstructured":"Liu, X. S. et al. Editing DNA methylation in the mammalian genome. Cell 167, 233\u2013247 (2016).","journal-title":"Cell"},{"key":"884_CR55","doi-asserted-by":"publisher","first-page":"46545","DOI":"10.18632\/oncotarget.10234","volume":"7","author":"SR Choudhury","year":"2016","unstructured":"Choudhury, S. R., Cui, Y., Lubecka, K., Stefanska, B. & Irudayaraj, J. CRISPR\u2013dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. Oncotarget 7, 46545 (2016).","journal-title":"Oncotarget"},{"key":"884_CR56","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.1038\/celldisc.2016.9","volume":"2","author":"X Xu","year":"2016","unstructured":"Xu, X. et al. A CRISPR-based approach for targeted DNA demethylation. Cell Discov. 2, 16009 (2016).","journal-title":"Cell Discov."},{"key":"884_CR57","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/nbt.3658","volume":"34","author":"S Morita","year":"2016","unstructured":"Morita, S. et al. Targeted DNA demethylation in vivo using dCas9\u2013peptide repeat and scFv\u2013TET1 catalytic domain fusions. Nat. Biotechnol. 34, 1060\u20131065 (2016).","journal-title":"Nat. Biotechnol."},{"key":"884_CR58","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","volume":"184","author":"JK Nu\u00f1ez","year":"2021","unstructured":"Nu\u00f1ez, J. K. et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell 184, 2503\u20132519 (2021).","journal-title":"Cell"},{"key":"884_CR59","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2018.01.012","volume":"172","author":"XS Liu","year":"2018","unstructured":"Liu, X. S. et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172, 979\u2013992 (2018).","journal-title":"Cell"},{"key":"884_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add4666","volume":"15","author":"J Qian","year":"2023","unstructured":"Qian, J. et al. Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons. Sci. Transl. Med. 15, eadd4666 (2023).","journal-title":"Sci. Transl. Med."},{"key":"884_CR61","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","volume":"588","author":"M Litvi\u0148ukov\u00e1","year":"2020","unstructured":"Litvi\u0148ukov\u00e1, M. et al. Cells of the adult human heart. Nature 588, 466\u2013472 (2020).","journal-title":"Nature"},{"key":"884_CR62","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1093\/hmg\/ddaa267","volume":"29","author":"LN Rodden","year":"2020","unstructured":"Rodden, L. N. et al. Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia. Hum. Mol. Genet. 29, 3818\u20133829 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"884_CR63","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cvr\/cvae207","volume":"120","author":"L Grisorio","year":"2024","unstructured":"Grisorio, L., Bongianino, R., Gianeselli, M. & Priori, S. G. Gene therapy for cardiac diseases: methods, challenges, and future directions. Cardiovasc. Res. 120, 1664\u20131682 (2024).","journal-title":"Cardiovasc. Res."},{"key":"884_CR64","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1101\/gr.082701.108","volume":"19","author":"RC Friedman","year":"2009","unstructured":"Friedman, R. C., Farh, K. K.-H., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92\u2013105 (2009).","journal-title":"Genome Res."},{"key":"884_CR65","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2215\/CJN.0000000000000458","volume":"19","author":"DP Gale","year":"2024","unstructured":"Gale, D. P. et al. A randomized controlled clinical trial testing effects of lademirsen on kidney function decline in adults with Alport syndrome. Clin. J. Am. Soc. Nephrol. 19, 995\u20131004 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"884_CR66","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/ijms25031469","volume":"25","author":"AA Seyhan","year":"2024","unstructured":"Seyhan, A. A. Trials and tribulations of microRNA therapeutics. Int. J. Mol. Sci. 25, 1469 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"884_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140759","volume":"5","author":"G-J Kang","year":"2020","unstructured":"Kang, G.-J., Xie, A., Liu, H. & Dudley, S. C. Jr. MIR448 antagomir reduces arrhythmic risk after myocardial infarction by upregulating the cardiac sodium channel. JCI Insight 5, e140759 (2020).","journal-title":"JCI Insight"},{"key":"884_CR68","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.111.030932","volume":"124","author":"RL Montgomery","year":"2011","unstructured":"Montgomery, R. L. et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124, 1537\u20131547 (2011).","journal-title":"Circulation"},{"key":"884_CR69","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nature07511","volume":"456","author":"T Thum","year":"2008","unstructured":"Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980\u2013984 (2008).","journal-title":"Nature"},{"key":"884_CR70","doi-asserted-by":"crossref","unstructured":"Bauersachs, J. et al. The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial. Nat. Med. 32, 2654\u20132661 (2026).","DOI":"10.1038\/s41591-026-04408-4"},{"key":"884_CR71","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41576-024-00723-z","volume":"25","author":"A Werner","year":"2024","unstructured":"Werner, A., Kanhere, A., Wahlestedt, C. & Mattick, J. S. Natural antisense transcripts as versatile regulators of gene expression. Nat. Rev. Genet. 25, 730\u2013744 (2024).","journal-title":"Nat. Rev. Genet."},{"key":"884_CR72","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2158","volume":"30","author":"F Modarresi","year":"2012","unstructured":"Modarresi, F. et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 30, 453\u2013459 (2012).","journal-title":"Nat. Biotechnol."},{"key":"884_CR73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ebiom.2016.05.011","volume":"9","author":"J Hsiao","year":"2016","unstructured":"Hsiao, J. et al. Upregulation of haploinsufficient gene expression in the brain by targeting a long non-coding RNA improves seizure phenotype in a model of Dravet syndrome. EBioMedicine 9, 257\u2013277 (2016).","journal-title":"EBioMedicine"},{"key":"884_CR74","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41591-025-03784-7","volume":"31","author":"JF Hipp","year":"2025","unstructured":"Hipp, J. F. et al. The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial. Nat. Med. 31, 2936\u20132945 (2025).","journal-title":"Nat. Med."},{"key":"884_CR75","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00439-025-02761-x","volume":"144","author":"L Foco","year":"2025","unstructured":"Foco, L. et al. Genomic and molecular evidence that the lncRNA DSP-AS1 modulates desmoplakin expression. Hum. Genet. 144, 843\u2013860 (2025). Identified a natural antisense transcript regulating DSP expression and demonstrated that inhibition of this transcript increases DSP expression in hiPSC-derived cardiomyocytes, providing an example of therapeutic derepression of a haploinsufficient cardiomyopathy gene.","journal-title":"Hum. Genet."},{"key":"884_CR76","doi-asserted-by":"crossref","unstructured":"Celik, S. et al. Antisense-mediated regulation of exon usage in the elastic spring region of titin modulates sarcomere function. Cardiovasc. Res. 121, 629\u2013642 (2025).","DOI":"10.1093\/cvr\/cvaf037"},{"key":"884_CR77","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238\u2013248 (2017).","journal-title":"Nat. Biotechnol."},{"key":"884_CR78","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41576-020-0258-4","volume":"21","author":"C Buccitelli","year":"2020","unstructured":"Buccitelli, C. & Selbach, M. mRNAs, proteins and the emerging principles of gene expression control. Nat. Rev. Genet. 21, 630\u2013644 (2020).","journal-title":"Nat. Rev. Genet."},{"key":"884_CR79","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/ijms21041329","volume":"21","author":"M Ribeiro","year":"2020","unstructured":"Ribeiro, M., Furtado, M., Martins, S., Carvalho, T. & Carmo-Fonseca, M. RNA splicing defects in hypertrophic cardiomyopathy: implications for diagnosis and therapy. Int. J. Mol. Sci. 21, 1329 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"884_CR80","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/gt.2017.52","volume":"24","author":"K Talbot","year":"2017","unstructured":"Talbot, K. & Tizzano, E. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 24, 529\u2013533 (2017).","journal-title":"Gene Ther."},{"key":"884_CR81","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts, T. C., Wood, M. J. & Davies, K. E. Therapeutic approaches for Duchenne muscular dystrophy. Nat. Rev. Drug Discov. 22, 917\u2013934 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"884_CR82","doi-asserted-by":"publisher","first-page":"175675","DOI":"10.1016\/j.ejphar.2023.175675","volume":"947","author":"G Patterson","year":"2023","unstructured":"Patterson, G., Conner, H., Groneman, M., Blavo, C. & Parmar, M. S. Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach. Eur. J. Pharmacol. 947, 175675 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"884_CR83","doi-asserted-by":"publisher","first-page":"104457","DOI":"10.1016\/j.braindev.2025.104457","volume":"47","author":"Y Takeshima","year":"2025","unstructured":"Takeshima, Y., Lee, T. & Shimomura, H. Development and future prospects of exon-skipping therapy for Duchenne muscular dystrophy. Brain Dev. 47, 104457 (2025).","journal-title":"Brain Dev."},{"key":"884_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4324","volume":"5","author":"Y-L Min","year":"2019","unstructured":"Min, Y.-L. et al. CRISPR\u2013Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci. Adv. 5, eaav4324 (2019).","journal-title":"Sci. Adv."},{"key":"884_CR85","unstructured":"He, C. Xiao, G., Li, X. & Dai, Y. Positive cardiac and pulmonary functional improvements with the DMD base editor GEN6050X: one-year follow-up from an early phase I study. In Proc. MDA Clinical & Scientific Conference Poster Number 21 S (MDA, 2026)."},{"key":"884_CR86","doi-asserted-by":"publisher","first-page":"562","DOI":"10.15252\/emmm.201505047","volume":"7","author":"M Gramlich","year":"2015","unstructured":"Gramlich, M. et al. Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol. Med. 7, 562\u2013576 (2015).","journal-title":"EMBO Mol. Med."},{"key":"884_CR87","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/emmm.201202168","volume":"5","author":"C Gedicke-Hornung","year":"2013","unstructured":"Gedicke-Hornung, C. et al. Rescue of cardiomyopathy through U7sn RNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol. Med. 5, 1128\u20131145 (2013).","journal-title":"EMBO Mol. Med."},{"key":"884_CR88","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","volume":"7","author":"M Prondzynski","year":"2017","unstructured":"Prondzynski, M. et al. Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes. Mol. Ther. Nucleic Acids 7, 475\u2013486 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"884_CR89","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1038\/mtna.2013.31","volume":"2","author":"G Mearini","year":"2013","unstructured":"Mearini, G. et al. Repair of Mybpc3 mRNA by 5\u2032-trans-splicing in a mouse model of hypertrophic cardiomyopathy. Mol. Ther. Nucleic Acids 2, e102 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"884_CR90","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1073\/pnas.0810916106","volume":"106","author":"SE Calvo","year":"2009","unstructured":"Calvo, S. E., Pagliarini, D. J. & Mootha, V. K. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. Proc. Natl Acad. Sci. USA 106, 7507\u20137512 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"884_CR91","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nbt.3589","volume":"34","author":"X-H Liang","year":"2016","unstructured":"Liang, X.-H. et al. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat. Biotechnol. 34, 875\u2013880 (2016).","journal-title":"Nat. Biotechnol."},{"key":"884_CR92","doi-asserted-by":"publisher","first-page":"102406","DOI":"10.1016\/j.omtn.2024.102406","volume":"36","author":"N Ahlskog","year":"2025","unstructured":"Ahlskog, N. et al. uORF-targeting steric block antisense oligonucleotides do not reproducibly increase RNASEH1 expression. Mol. Ther. Nucleic Acids 36, 102406 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"884_CR93","doi-asserted-by":"publisher","first-page":"9528","DOI":"10.1093\/nar\/gkx632","volume":"45","author":"X-H Liang","year":"2017","unstructured":"Liang, X.-H. et al. Antisense oligonucleotides targeting translation inhibitory elements in 5\u2032 UTRs can selectively increase protein levels. Nucleic Acids Res. 45, 9528\u20139546 (2017).","journal-title":"Nucleic Acids Res."},{"key":"884_CR94","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ymthe.2019.06.016","volume":"27","author":"S Sasaki","year":"2019","unstructured":"Sasaki, S. et al. Steric inhibition of 5\u2032 UTR regulatory elements results in upregulation of human CFTR. Mol. Ther. 27, 1749\u20131757 (2019).","journal-title":"Mol. Ther."},{"key":"884_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41799-1","volume":"14","author":"OM Hedaya","year":"2023","unstructured":"Hedaya, O. M. et al. Secondary structures that regulate mRNA translation provide insights for ASO-mediated modulation of cardiac hypertrophy. Nat. Commun. 14, 6166 (2023). Identified a repressive RNA structure in the 5\u02b9 UTR of GATA4 and demonstrated that ASO-mediated disruption of this element increases GATA4 protein expression in hiPS cell-derived cardiomyocytes, providing proof of concept for therapeutically targeting translational repression in cardiac cells.","journal-title":"Nat. Commun."},{"key":"884_CR96","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.omtn.2020.12.027","volume":"23","author":"AM Winkelsas","year":"2021","unstructured":"Winkelsas, A. M. et al. Targeting the 5\u2032 untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy. Mol. Ther. Nucleic Acids 23, 731\u2013742 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"884_CR97","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.1093\/nar\/gkab954","volume":"49","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Targeting 3\u2032 and 5\u2032 untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res. 49, 11560\u201311574 (2021).","journal-title":"Nucleic Acids Res."},{"key":"884_CR98","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.2023020400","volume":"142","author":"Z Ang","year":"2023","unstructured":"Ang, Z. et al. Alternative splicing of its 5\u2032-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood 142, 1724\u20131739 (2023).","journal-title":"Blood"},{"key":"884_CR99","doi-asserted-by":"crossref","unstructured":"Feng, N. et al. Targeted BDNF upregulation via upstream open reading frame disruption. Mol. Ther. 34, 1652\u20131671 (2026).","DOI":"10.1016\/j.ymthe.2025.12.024"},{"key":"884_CR100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbrc.2014.09.085","volume":"453","author":"AG Cadar","year":"2014","unstructured":"Cadar, A. G., Zhong, L., Lin, A., Valenzuela, M. O. & Lim, C. C. Upstream open reading frame in 5\u2032-untranslated region reduces titin mRNA translational efficiency. Biochem. Biophys. Res. Commun. 453, 185\u2013191 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"884_CR101","doi-asserted-by":"publisher","first-page":"103077","DOI":"10.1016\/j.omtn.2026.103077","volume":"37","author":"RB Kirk","year":"2026","unstructured":"Kirk, R. B. et al. Functional analysis of TTN uORFs reveals context-dependent translational regulation. Mol. Ther. Nucleic Acids 37, 103077 (2026).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"884_CR102","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2020.02.031","volume":"180","author":"EZ Kvon","year":"2020","unstructured":"Kvon, E. Z. et al. Comprehensive in vivo interrogation reveals phenotypic impact of human enhancer variants. Cell 180, 1262\u20131271 (2020).","journal-title":"Cell"},{"key":"884_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55900-3","volume":"16","author":"H Ray-Jones","year":"2025","unstructured":"Ray-Jones, H. et al. Genetic coupling of enhancer activity and connectivity in gene expression control. Nat. Commun. 16, 970 (2025).","journal-title":"Nat. Commun."},{"key":"884_CR104","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41588-023-01434-7","volume":"55","author":"T Mayuranathan","year":"2023","unstructured":"Mayuranathan, T. et al. Potent and uniform fetal hemoglobin induction via base editing. Nat. Genet. 55, 1210\u20131220 (2023).","journal-title":"Nat. Genet."},{"key":"884_CR105","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41596-023-00817-8","volume":"18","author":"JC Hamley","year":"2023","unstructured":"Hamley, J. C., Li, H., Denny, N., Downes, D. & Davies, J. O. Determining chromatin architecture with Micro Capture-C. Nat. Protoc. 18, 1687\u20131711 (2023).","journal-title":"Nat. Protoc."},{"key":"884_CR106","doi-asserted-by":"publisher","first-page":"e183353","DOI":"10.1172\/JCI183353","volume":"135","author":"Y Kim","year":"2025","unstructured":"Kim, Y. et al. Regulation of sarcomere formation and function in the healthy heart requires a titin intronic enhancer. J. Clin. Invest. 135, e183353 (2025). Identified and functionally characterized a cardiac TTN enhancer, revealing sequence motifs that alter TTN expression and that could be targets for therapeutic upregulation of titin.","journal-title":"J. Clin. Invest."},{"key":"884_CR107","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nmeth.3312","volume":"12","author":"A Chavez","year":"2015","unstructured":"Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12, 326\u2013328 (2015).","journal-title":"Nat. Methods"},{"key":"884_CR108","doi-asserted-by":"publisher","unstructured":"Smith, E. D. et al. Desmoplakin haploinsufficiency underlies cell\u2013cell adhesion failure in DSP cardiomyopathy and is rescued by transcriptional activation. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.06.01.657304 (2025).","DOI":"10.1101\/2025.06.01.657304"},{"key":"884_CR109","doi-asserted-by":"crossref","unstructured":"Ca\u00f1as-Alvaro, R. et al. CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. Eur. Heart J. 46, 4610\u20134613 (2025). Demonstrated that AAV-delivered CRISPRa can increase FLNC expression in vivo and reverse electrical abnormalities in a mouse model of FLNC haploinsufficiency, providing preclinical evidence that endogenous gene activation can rescue a cardiomyopathy phenotype.","DOI":"10.1093\/eurheartj\/ehaf703"},{"key":"884_CR110","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"884_CR111","doi-asserted-by":"publisher","first-page":"952755","DOI":"10.3389\/fcvm.2022.952755","volume":"9","author":"H Zhang","year":"2022","unstructured":"Zhang, H., Zhan, Q., Huang, B., Wang, Y. & Wang, X. AAV-mediated gene therapy: advancing cardiovascular disease treatment. Front. Cardiovasc. Med. 9, 952755 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"884_CR112","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","volume":"31","author":"L Bendixen","year":"2023","unstructured":"Bendixen, L., Jensen, T. I. & Bak, R. O. CRISPR\u2013Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi. Mol. Ther. 31, 1920\u20131937 (2023).","journal-title":"Mol. Ther."},{"key":"884_CR113","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/gt.2016.36","volume":"23","author":"P Chapdelaine","year":"2016","unstructured":"Chapdelaine, P. et al. Development of an AAV9 coding for a 3\u00d7Flag-TALEfrat# 8-VP64 able to increase in vivo the human frataxin in YG8R mice. Gene Ther. 23, 606\u2013614 (2016).","journal-title":"Gene Ther."},{"key":"884_CR114","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.omtn.2018.04.009","volume":"12","author":"K Cherif","year":"2018","unstructured":"Cherif, K. et al. Increased frataxin expression induced in Friedreich ataxia cells by platinum TALE-VP64s or platinum TALE-SunTag. Mol. Ther. Nucleic Acids 12, 19\u201332 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"884_CR115","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.omtm.2019.02.004","volume":"13","author":"S Zhang","year":"2019","unstructured":"Zhang, S., Chen, H. & Wang, J. Generate TALE\/TALEN as easily and rapidly as generating CRISPR. Mol. Ther. Methods Clin. Dev. 13, 310\u2013320 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"884_CR116","doi-asserted-by":"publisher","first-page":"17337","DOI":"10.1073\/pnas.0607015103","volume":"103","author":"L-C Li","year":"2006","unstructured":"Li, L.-C. et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl Acad. Sci. USA 103, 17337\u201317342 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"884_CR117","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/cr.2016.22","volume":"26","author":"V Portnoy","year":"2016","unstructured":"Portnoy, V. et al. saRNA-guided AGO2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 26, 320\u2013335 (2016).","journal-title":"Cell Res."},{"key":"884_CR118","first-page":"3936","volume":"26","author":"D Sarker","year":"2020","unstructured":"Sarker, D. et al. MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-\u03b1, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial. Circ. Cancer Res. 26, 3936\u20133946 (2020).","journal-title":"Circ. Cancer Res."},{"key":"884_CR119","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/cvr\/cvae116","volume":"120","author":"R Yang","year":"2024","unstructured":"Yang, R. et al. Cardiomyocyte \u03b2II spectrin plays a critical role in maintaining cardiac function by regulating mitochondrial respiratory function. Cardiovasc. Res. 120, 1312\u20131326 (2024).","journal-title":"Cardiovasc. Res."},{"key":"884_CR120","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nature11508","volume":"491","author":"C Carrieri","year":"2012","unstructured":"Carrieri, C. et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature 491, 454\u2013457 (2012). Identified a natural antisense lncRNA containing a SINEB2 element that selectively enhances translation of its target mRNA, establishing the mechanistic basis for the subsequent development of synthetic SINEUP gene-upregulation technologies.","journal-title":"Nature"},{"key":"884_CR121","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/15476286.2015.1060395","volume":"12","author":"S Zucchelli","year":"2015","unstructured":"Zucchelli, S. et al. SINEUPs: a new class of natural and synthetic antisense long non-coding RNAs that activate translation. RNA Biol. 12, 771\u2013779 (2015).","journal-title":"RNA Biol"},{"key":"884_CR122","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1042\/EBC20200114","volume":"65","author":"S Espinoza","year":"2021","unstructured":"Espinoza, S. et al. SINEUPs: a novel toolbox for RNA therapeutics. Essays Biochem. 65, 775\u2013789 (2021).","journal-title":"Essays Biochem."},{"key":"884_CR123","doi-asserted-by":"publisher","first-page":"10728","DOI":"10.1093\/nar\/gkz798","volume":"47","author":"C Bon","year":"2019","unstructured":"Bon, C. et al. SINEUP non-coding RNAs rescue defective frataxin expression and activity in a cellular model of Friedreich\u2019s ataxia. Nucleic Acids Res. 47, 10728\u201310743 (2019).","journal-title":"Nucleic Acids Res."},{"key":"884_CR124","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ymthe.2019.08.005","volume":"28","author":"S Espinoza","year":"2020","unstructured":"Espinoza, S. et al. SINEUP non-coding RNA targeting GDNF rescues motor deficits and neurodegeneration in a mouse model of Parkinson\u2019s disease. Mol. Ther. 28, 642\u2013652 (2020).","journal-title":"Mol. Ther."},{"key":"884_CR125","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1093\/nar\/gkad010","volume":"51","author":"C Cao","year":"2023","unstructured":"Cao, C. et al. Enhancement of protein translation by CRISPR\/dCasRx coupled with SINEB2 repeat of noncoding RNAs. Nucleic Acids Res. 51, e33 (2023).","journal-title":"Nucleic Acids Res."},{"key":"884_CR126","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cell.2019.05.049","volume":"178","author":"S Rauch","year":"2019","unstructured":"Rauch, S. et al. Programmable RNA-guided RNA effector proteins built from human parts. Cell 178, 122\u2013134 (2019).","journal-title":"Cell"},{"key":"884_CR127","doi-asserted-by":"publisher","first-page":"gkag113","DOI":"10.1093\/nar\/gkag113","volume":"54","author":"RW Sinnott","year":"2026","unstructured":"Sinnott, R. W., Solanki, A., Govind, A. P., Green, W. N. & Dickinson, B. C. Engineering a human-based translational activator for targeted protein expression restoration. Nucleic Acids Res. 54, gkag113 (2026).","journal-title":"Nucleic Acids Res."},{"key":"884_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42252-z","volume":"14","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. RNA-based translation activators for targeted gene upregulation. Nat. Commun. 14, 6827 (2023).","journal-title":"Nat. Commun."},{"key":"884_CR129","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.hlc.2023.06.704","volume":"32","author":"N Sasaki","year":"2023","unstructured":"Sasaki, N. et al. In search of adeno-associated virus vectors with enhanced cardiac tropism for gene therapy. Heart Lung Circ. 32, 816\u2013824 (2023).","journal-title":"Heart Lung Circ."},{"key":"884_CR130","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.ymthe.2025.01.041","volume":"33","author":"CJ Walkey","year":"2025","unstructured":"Walkey, C. J. et al. A comprehensive atlas of AAV tropism in the mouse. Mol. Ther. 33, 1282\u20131299 (2025).","journal-title":"Mol. Ther."},{"key":"884_CR131","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229\u2013236 (2020).","journal-title":"Nature"},{"key":"884_CR132","doi-asserted-by":"publisher","first-page":"1138596","DOI":"10.3389\/fbioe.2023.1138596","volume":"11","author":"R Ewaisha","year":"2023","unstructured":"Ewaisha, R. & Anderson, K. S. Immunogenicity of CRISPR therapeutics\u2014critical considerations for clinical translation. Front. Bioeng. Biotechnol. 11, 1138596 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"884_CR133","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.omtm.2023.08.010","volume":"30","author":"CY Kok","year":"2023","unstructured":"Kok, C. Y. et al. Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes. Mol. Ther. Methods Clin. Dev. 30, 459\u2013473 (2023). Used directed evolution and iterative selection in hiPSC-derived cardiomyocytes to develop AAV capsids with enhanced cardiac transduction, demonstrating an approach to improving the cardiac specificity of gene therapy delivery.","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"884_CR134","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi, S., Jaafari, M. R. & Arabi, L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J. Control Release 372, 113\u2013140 (2024).","journal-title":"J. Control Release"},{"key":"884_CR135","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCRESAHA.118.311587","volume":"123","author":"K Ishikawa","year":"2018","unstructured":"Ishikawa, K., Weber, T. & Hajjar, R. J. Human cardiac gene therapy. Circ. Res. 123, 601\u2013613 (2018).","journal-title":"Circ. Res."},{"key":"884_CR136","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.tibtech.2022.11.006","volume":"41","author":"J Earley","year":"2023","unstructured":"Earley, J., Piletska, E., Ronzitti, G. & Piletsky, S. Evading and overcoming AAV neutralization in gene therapy. Trends Biotechnol. 41, 836\u2013845 (2023).","journal-title":"Trends Biotechnol."},{"key":"884_CR137","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ejhf.3139","volume":"26","author":"J Bauersachs","year":"2024","unstructured":"Bauersachs, J. et al. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: rationale and design of the HF-REVERT trial. Eur. J. Heart Fail. 26, 674\u2013682 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"884_CR138","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac159","volume":"23","author":"Z Lou","year":"2022","unstructured":"Lou, Z. et al. Predicting miRNA\u2013disease associations via learning multimodal networks and fusing mixed neighborhood information. Brief. Bioinform. 23, bbac159 (2022).","journal-title":"Brief. Bioinform."},{"key":"884_CR139","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/bfgp\/ely031","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Computational models for lncRNA function prediction and functional similarity calculation. Brief. Funct. Genomics 18, 58\u201382 (2019).","journal-title":"Brief. Funct. Genomics"},{"key":"884_CR140","doi-asserted-by":"publisher","unstructured":"Hanson, B. et al. Toward a model of uORF-mediated translational control: an integrated bioinformatic and experimental approach. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.07.28.667205 (2025).","DOI":"10.1101\/2025.07.28.667205"},{"key":"884_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19099-3","volume":"12","author":"AH Butt","year":"2022","unstructured":"Butt, A. H., Alkhalifah, T., Alturise, F. & Khan, Y. D. A machine learning technique for identifying DNA enhancer regions utilizing cis-regulatory element patterns. Sci. Rep. 12, 15183 (2022).","journal-title":"Sci. Rep."},{"key":"884_CR142","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41586-025-10014-0","volume":"649","author":"\u017d Avsec","year":"2026","unstructured":"Avsec, \u017d et al. Advancing regulatory variant effect prediction with AlphaGenome. Nature 649, 1206\u20131218 (2026).","journal-title":"Nature"},{"key":"884_CR143","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.cell.2025.01.011","volume":"188","author":"VN Parikh","year":"2025","unstructured":"Parikh, V. N. et al. Advances in the study and treatment of genetic cardiomyopathies. Cell 188, 901\u2013918 (2025).","journal-title":"Cell"},{"key":"884_CR144","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/eurheartj\/ehz933","volume":"41","author":"N Cesarovic","year":"2020","unstructured":"Cesarovic, N., Lipiski, M., Falk, V. & Emmert, M. Y. Animals in cardiovascular research: clinical relevance and translational limitations of animal models in cardiovascular medicine. Eur. Heart J. 41, 200\u2013203 (2020).","journal-title":"Eur. Heart J."},{"key":"884_CR145","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-025-02598-8","volume":"24","author":"Z Huang","year":"2025","unstructured":"Huang, Z. et al. Advances in cardiac organoid research: implications for cardiovascular disease treatment. Cardiovasc. Diabetol. 24, 25 (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"884_CR146","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41573-025-01317-y","volume":"25","author":"D Wang","year":"2026","unstructured":"Wang, D., Villenave, R., Stokar-Regenscheit, N. & Clevers, H. Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges. Nat. Rev. Drug Discov. 25, 204\u2013226 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"884_CR147","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cardfail.2025.11.065","volume":"32","author":"B Greenberg","year":"2026","unstructured":"Greenberg, B. et al. A first-in-human phase I study demonstrating safety, tolerability, and preliminary efficacy of RP-A601, an AAV-mediated gene therapy (AAVrh. 74-PKP2a) in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM). J. Card. Fail. 32, 199 (2026).","journal-title":"J. Card. Fail."},{"key":"884_CR148","unstructured":"US National Library of Medicine. A phase 1 AAV gene therapy trial evaluating safety and preliminary efficacy of RP-A701 in subjects with BAG3 dilated cardiomyopathy. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07137338 (2026)."},{"key":"884_CR149","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"884_CR150","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00884-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00884-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00884-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:03:24Z","timestamp":1791957804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00884-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":150,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00884-6","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.W. reports consultancies for Cytokinetics, BioMarin, Astra Zeneca and CardiaTec and is a founder and director of Cora Biosciences. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}